A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

NCT02665143 | Completed Phase 2 Results DMC

• 1 other identifier: 1507016193
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to determine if a combination of nintedanib+ induction chemotherapy can be an effective strategy for patients where outcome of relapse/refractory acute myeloid leukemia (AML) is poor.

Conditions

Relapsed/Refractory Acute Myeloid Leukemia

Keywords

acute myeloid leukemia

Outcome Measures

Primary Outcomes (2)

• Count of Patients With Treatment-Emergent Adverse Events (Phase 1)

  In the Phase 1 portion of the study, safety will be assessed after the inclusion of the first 6 patients, to analyze tolerance and adverse events occurring during this trial and will decide on any action to be taken. Safety will be evaluated according to NCI CTCAE V4 criteria. TEAE's were considered adverse events that occurred within 60 days of treatment initiation. The title of this outcome measure was adjusted when results were entered.

  60 days

• Complete Remission Rate (Phase 2)

  In Phase 2, the primary endpoint of complete remission rate will be based on IWG 2003 AML response criteria. This construct is an overall response composite and it will be assessed using the following metrics: Morphologic complete remission (CR): ANC ≥ 1,000/mcl, platelet count ≥ 100,000/mcl, \< 5% bone marrow blasts, no Auer rods, no evidence of extramedullary disease. (No requirements for marrow cellularity, hemoglobin concentration). Morphologic complete remission with incomplete blood count recovery (CRi): Same as CR but ANC may be \< 1,000/mcl but \>500 mcl and/or platelet count \< 100,000/mcl but \>20,000/mcl Partial remission (PR): ANC ≥ 1,000/mcl, platelet count \> 100,000/mcl, and at least a 50% decrease in the percentage of marrow aspirate blasts to 5-25%, or marrow blasts \< 5% with persistent Auer rods. Marrow Leukemia Free State: \< 5% bone marrow blasts, no Auer rods, no extra medullary disease. No requirement on cytopenias.

  Up to 2 years

Secondary Outcomes (1)

• Incidence of Hematological Improvement (Phase 2)

  Up to 2 years

Study Arms (1)

Nintedanib and AML induction

EXPERIMENTAL

The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. Based on the phase I dose, in the randomized phase II, the combination will be compared with chemotherapy+placebo. Nintedanib or placebo will be added at day 8 and continued until end of cycle .

Drug: Nintedanib and AML induction

Interventions

Nintedanib and AML induction DRUG

The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. In the phase I part, all patients will receive the combination with Nintedanib 200mg bid begun at day 8 and continued until end of cycle. If a significant incidence of dose limiting toxicities is demonstrated, Nintedanib will be given at a lower dose level (150mg bid).

Also known as: Phase II Open Label

Nintedanib and AML induction

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of AML according to WHO 2008 criteria. Therapy related AML may be included if off treatment for their prior malignancy for more than 2 years and in complete remission. AML arising after documented MPD is excluded.
• Patient must meet one of the following criteria: a/ patient refractory to one or two standard induction regimens b/ patients with a first untreated relapse within 2 years of documentation of complete remission. Patients relapsing after allogeneic stem cell transplantation are eligible if more than 6 months after transplantation and without signs of active GVHD.
• ECOG performance status of 2 or less
• Patient is willing to participate to the study, has the ability to adhere to the study visit schedule and other protocol procedures, and has the ability to understand and sign an inform consent form.
• Women of childbearing potential must agree to use effective contraception without interruption throughout the study and for 3 months after the end of treatment;
• Men must agree to not conceive during the treatment and to use effective contraception during the treatment period (including periods of dose reduction or temporary suspension) and for 3 months after the end of treatment if their partner is of childbearing potential.

You may not qualify if:

• Patient with documented acute promyelocytic leukemia and/or PML-RAR transcript.
• Patient relapsing more than 2 years after initial remission.
• Use of any active treatment for relapse including but not restricted to chemotherapy, targeted agents, hypomethylating agents or investigational drugs. Use of hydroxyurea up to 6g per day for cytoreduction is allowed for a maximum of 30 days prior treatment.
• Patients with clinical evidence of active CNS disease at enrollment
• LVEF below 45% or lifetime exposure to anthracyclines over 350mg/m2 of daunorubicin equivalent
• Liver function tests: ASAT ALAT above 2.5 ULN, total bilirubin above 2.5 ULN in the absence of Hemolysis or diagnosis of Gilbert's syndrome
• Serum creatinine above 2.0mg/dl
• Any sign of active uncontrolled disease including but not restricted to cardiac disease, infections, hepatitis. Any severe chronic disease potentially interfering with the protocol including HIV infection, active hepatitis B or C. It includes major injuries and/or surgery within the past 4 weeks prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period.
• Documented platelet refractoriness
• Patient has a history of GI surgery, procedures or conditions that might interfere with the absorption or swallowing of the study drugs .
• Women who are or pregnant, or who are currently breastfeeding
• Prior treatment with nintedanib or any other VEGFR inhibitor
• Known hypersensitivity to nintedanib, any other trial drug, or their excipients
• Persistence of any clinically relevant (CTCAE grade 2 or above) non-hematological toxicities from previous AML therapy
• Active alcohol or drug abuse

Sponsors & Collaborators

• Yale University: lead
• Vanderbilt University: collaborator

Study Sites (2)

Yale University

New Haven, Connecticut, 06520, United States

Location

Vanderbilt Ingram Cancer Center

Nashville, Tennessee, 37232, United States

Location

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Interventions

nintedanib

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Results Point of Contact

• Title: Thomas Prebet, MD, PhD
• Organization: Yale School of Medicine

thomas.prebet@yale.edu

(203) 200-4363

Study Officials

• Thomas Prebet, MD,PhD

  Yale University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 20, 2016
• First Posted: January 27, 2016
• Study Start: July 21, 2016
• Primary Completion: March 8, 2021
• Study Completion: March 30, 2021
• Last Updated: April 8, 2022
• Results First Posted: April 8, 2022

Record last verified: 2022-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)